Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rwj-67657. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 known ✓ | Q16539 | 19/20 | 1.00 |
| ▸ | MAPK11 known ✓ | Q15759 | 5/20 | 0.62 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.62 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.44 |
| ▸ | GCGR | P47871 | 1/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.43 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12856400 | 1.00 | MAPK14 (1.00) | MAPK14MAPK11MAP4K4MAPK13MAPK12 | |
| Rwj-67657 SCHEMBL5815060 | 0.99 | MAPK14 (0.98) | MAPK14MAPK11MAP4K4MAPK13MAPK12 | |
| SCHEMBL5999009 | 0.95 | MAPK14 (0.91) | MAPK14MAPK11MAP4K4MAPK13MAPK12 | |
| SCHEMBL7145536 | 0.94 | MAPK14 (0.89) | MAPK14MAPK11MAP4K4MAPK13MAPK12 | |
| SCHEMBL5998654 | 0.93 | MAPK14 (0.87) | MAPK14MAPK11MAP4K4MAPK13MAPK12 | |
| SCHEMBL5820266 | 0.92 | MAPK14 (0.85) | MAPK14MAPK11MAP4K4MAPK13MAPK12 | |
| SCHEMBL13035057 | 0.90 | MAPK14 (0.82) | MAPK14MAPK11MAP4K4MAPK13MAPK12 | |
| SCHEMBL7141213 | 0.90 | MAPK14 (0.82) | MAPK14MAPK11MAP4K4MAPK13MAPK12 | |
| SCHEMBL1127681 | 0.90 | MAPK14 (0.81) | MAPK14MAPK11MAP4K4MAPK13MAPK12 | |
| SCHEMBL5997587 | 0.89 | MAPK14 (0.80) | MAPK14MAPK11MAP4K4MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 805 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215397-A1 | TWO-DIMENSIONAL CULTURE METHOD HAVING CLEAR CHEMICAL COMPOSITION FOR CULTURING THREE-DIMENSIONAL INTESTINAL ORGANOID-DERIVED INTESTINAL STEM CELL AGGREGATE | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2025-07-03 | — | — | US | claimed |
| CN-119698462-A | Two-dimensional culture method with definite chemical composition for culturing three-dimensional intestinal organoid derived intestinal stem cell population | 韩国生命工学研究院 | 2025-03-25 | — | — | CN | claimed |
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | Poolbeg Pharma (UK) Limited (GB) | 2024-11-19 | — | — | US | claimed |
| US-20240316055-A1 | METHODS FOR TREATING LEIGH SYNDROME | DBCC RES LLC (US) | 2024-09-26 | — | — | US | claimed |
| EP-4416268-A1 | METHODS FOR PRODUCING CARTILAGE AND BONES | Murdoch Children's Research Institute (AU) | 2024-08-21 | — | — | EP | claimed |
| CN-118355110-A | Method for producing cartilage and bone | 默多克儿童研究所 | 2024-07-16 | — | — | CN | claimed |
| US-20240228552-A9 | NANOPORE TWEEZER APPROACH FOR PROTEIN KINASE ALLOSTERIC DRUG SCREENING | UNIVERSITY OF MASSACHUSETTS | 2024-07-11 | — | — | US | claimed |
| CN-118105493-A | Skeletal muscle generation inducer, pharmaceutical composition, kit and application thereof | 北京大学 | 2024-05-31 | — | — | CN | claimed |
| WO-2024112170-A1 | METHOD FOR NON-XENOGENEIC CULTURING OF INTESTINAL STEM CELLS ON SURFACE COATED WITH THIN FILM | 한국생명공학연구원 | 2024-05-30 | — | — | WO | claimed |
| US-20240132551-A1 | NANOPORE TWEEZER APPROACH FOR PROTEIN KINASE ALLOSTERIC DRUG SCREENING | UNIV MASSACHUSETTS (US) | 2024-04-25 | — | — | US | claimed |
| US-20130337564-A1 | Treatment of Pluripotent Cells | JANSSEN BIOTECH, INC. | 2013-12-19 | — | — | US | claimed |
| US-20130045957-A1 | Prevention of and Recovery from Drug-Induced Ototoxicity | OTONOMY, INC. (US) | 2013-02-21 | — | — | US | claimed |
| WO-2012112810-A1 | PREVENTION OF AND RECOVERY FROM DRUG-INDUCED OTOTOXICITY | OTONOMY, INC. (US) | 2012-08-23 | — | — | WO | claimed |
| US-20100098641-A1 | Monophosphates as Mutual Prodrugs of Anti-Inflammatory Signal Transduction Modulators (AISTM's) and Beta-Agonists for the Treatment of Pulmonary Inflammation and Bronchoconstriction | GILEAD SCIENCES, INC. | 2010-04-22 | — | — | US | claimed |
| US-20090325293-A1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH, INC. | 2009-12-31 | — | — | US | claimed |
| EP-1676574-A2 | Methods for promoting survival of transplanted tissues and cells | Johnson & Johnson Vision Care, Inc. (US) | 2006-07-05 | — | — | EP | claimed |
| EP-1028954-B1 | SUBSTITUTED IMIDAZOLES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | ORTHO MCNEIL PHARM INC (US) | 2003-07-02 | — | — | EP | claimed |
| EP-1028954-A1 | SUBSTITUTED IMIDAZOLES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2000-08-23 | — | — | EP | claimed |
| US-5965583-A | ANTIINFLAMMATORY AGENTS IN THE TREATMENT OF DISEASES ASSOCIATED WITH OVERPRODUCTION OF INFLAMMATORY CYTOKINES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1999-10-12 | — | — | US | claimed |
| WO-1998047892-A1 | SUBSTITUTED IMIDAZOLES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | ORTHO-MCNEIL CORPORATION, INC. (US) | 1998-10-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, CCL11 | MAPK14 14/4885MAPK11 26/4885MAP4K4 69/4885 |
| US-20130045957-A1 | Prevention of and Recovery from Drug-Induced Ototoxicity | OTC, SLC26A4, ALDH1A3 | MAPK14 3792/4885MAPK11 3513/4885MAP4K4 4575/4885 |
| US-20240316055-A1 | METHODS FOR TREATING LEIGH SYNDROME | ECHS1, GLS2, OAT | MAPK14 4665/4885MAPK11 4713/4885MAP4K4 3657/4885 |
| US-20100098641-A1 | Monophosphates as Mutual Prodrugs of Anti-Inflammatory Signal Transduction Modulators (AISTM's) and Beta-Agonists for the Treatment of Pulmonary Inflammation and Bronchoconstriction | ADRB1, ADRB2, PDE11A | MAPK14 1362/4885MAPK11 734/4885MAP4K4 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.